Oramed Pharmaceuticals (ORMP) Net Cash Flow (2010 - 2026)

Oramed Pharmaceuticals has reported Net Cash Flow for 17 years, with the latest figure at -$32.8 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 263.04% year-over-year to -$32.8 million; the trailing twelve-month figure through Mar 2026 stood at -$60.9 million (down 208.92% YoY), and the FY2025 full-year result was -$8.4 million, down 118.61% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$32.8 million, down from -$6.2 million in the prior quarter.
• The five-year high for Net Cash Flow was $66.2 million in Q2 2024, with the low at -$58.4 million in Q2 2025.
• Historically, Net Cash Flow has averaged -$809000.0 across 5 years, with a median of $1.9 million in 2022.
• The largest YoY upside for Net Cash Flow was 481.58% in 2024 against a maximum downside of 3263.72% in 2024.
• Oramed Pharmaceuticals' Net Cash Flow stood at $7.4 million in 2022, then tumbled by 51.46% to $3.6 million in 2023, then surged by 244.17% to $12.3 million in 2024, then slumped by 150.0% to -$6.2 million in 2025, then plunged by 432.02% to -$32.8 million in 2026.
• The last three Net Cash Flow figures came in at -$32.8 million (Q1 2026), -$6.2 million (Q4 2025), and $36.4 million (Q3 2025), per Business Quant data.